Stay updated with breaking news from Frederickw Gluck. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Forefront Analytics LLC decreased its position in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Rating) by 48.2% in the 4th quarter, HoldingsChannel reports. The fund owned 24,787 shares of the biotechnology company’s stock after selling 23,082 shares during the period. Forefront Analytics LLC’s holdings in CytomX Therapeutics were worth $40,000 as of its most […]
Pasithea Therapeutics (NASDAQ:KTTA – Get Rating) and CytomX Therapeutics (NASDAQ:CTMX – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation. Profitability This table compares Pasithea Therapeutics and CytomX Therapeutics’ […]
CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Rating) was the recipient of a significant drop in short interest in May. As of May 15th, there was short interest totalling 2,130,000 shares, a drop of 13.4% from the April 30th total of 2,460,000 shares. Based on an average daily volume of 758,700 shares, the short-interest ratio is […]
CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Rating) has earned a consensus rating of “Hold” from the twelve analysts that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating on the company. The average 1 […]
CytomX Therapeutics, Inc. (NASDAQ:CTMX – Get Rating) was the recipient of a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 2,460,000 shares, an increase of 9.3% from the April 15th total of 2,250,000 shares. Based on an average daily trading volume, of 876,000 shares, […]